Compare Neurocrine Biosciences Inc (NBIX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sirius XM Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Sirius XM Holdings Inc trades at $26.51 (market cap $8.87B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Sirius XM Holdings Inc for 102 Days on average.
| NBIX | SIRI | |
|---|---|---|
Market Cap | $14.36B | $8.87B |
Volume | 1,237,180 | 4,324,672 |
Sector | Health | Media |
52-Week High | $185.50 | $32.59 |
52-Week Low | $123.10 | $19.92 |
Typical Hold Time | 23 Days | 102 Days |
Enterprise Value | $14.37B | $18.16B |
Dividend Yield | — | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Sirius XM Holdings (SIRI) trades at $26.33, up 1.46% with mixed technical signals showing neutral momentum. The stock presents attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, though recent earnings have been inconsistent with two misses in the last four quarters. Strong cash flow generation of $1.9B in 2025 supports the company's dividend payments and strategic initiatives, including recent YouTube advertising partnerships and technology leadership appointments.
SIRI offers value investment potential with upside to the $34.43 consensus price target, representing 31% potential return. However, investors face risks from inconsistent earnings performance and competitive pressures in the audio entertainment space. The company's improving balance sheet with debt-to-asset ratio declining to 35.63% provides financial stability, while institutional accumulation signals confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
